APLS (Apellis Pharmaceuticals, Inc.) שולי רווח נקי

לוגו גרפי של Apellis Pharmaceuticals, Inc. (APLS)

Apellis Pharmaceuticals (APLS) generates revenue from therapies for severe blood and vision pathologies. Final sales margins demonstrate a stable trend, with the value holding at 12.10. Growth is driven by Syfovre, a unique treatment for geographic atrophy with expansion potential into neurology. Scaling global supplies is activating operating leverage, contributing to a steady increase in net profit.

Apellis Pharmaceuticals (APLS) - שולי מכירות של החברה מ-04.07.2022 עד 30.05.2026

Apellis Corp (APLS) - פילוחי מדדים ודוחות פיננסיים

- שווי שוק ותחזית יעד של אנליסטים:
- מדדי הערכת שווי שוק של העסק:
ניתוח כללי של החברה:Apellis - APLS
מוצרים מוגמרים של Apellis Pharmaceuticals Inc

High R&D expenditures by Apellis Pharmaceuticals (APLS) for the development of targeted ophthalmological drugs directly impact overall business efficiency. By analyzing the net profit margin, an investor assesses the profit share of every dollar of revenue, which allows for the distinction between real operational returns and temporary financial spikes, and determines the balance between the risk of capitalization stagnation and asset reliability.